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PSA PERSPECTIVES: 
ASSESSING PATIENT KNOWLEDGE ABOUT 
PSA TESTING & FACILITATING A 
CONVERSATION ABOUT RISKS AND 
BENEFITS 
Kirsten Martin
Family Medicine Rotation 5, October-November, 2018
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Dr. Peter Anderson, MD
Problem Identification
• New recommendations from US Preventive Services Task Force 
(USPSTF) advise  physicians discuss the risks and benefits of PSA 
screening with men age 55-69 to determine who gets screened, after 
previously advising against screening altogether 
• Having a conversation about this screening test can take a significant 
amount of time to adequately educate patients about this 
controversial test 
• There are limited resources available to PCPs to facilitate this 
conversation. 
• Recommendations are conflicting and continue to change, further 
complicating the decision for patients and providers. 
Cost Considerations 
• The cost per year of life saved by prostate cancer 
screening with PSA and DRE was 
• $2339-3005 for men aged 50-59, 
• $3905-5070 for men aged 60-69, and 
• $3574-4627 overall for men aged 50-69
• Prostate cancer screening by Medicare amounted to 
$447 million in 2009 US dollars
• The 3-year cost to Medicare for prostate cancer 
detection in men 70 years or older is approximately $1.2 
billion. 
Community (Patient) Perspective
• The majority of men interviewed reported that they knew 
very little about prostate cancer screening and prostate 
cancer.
• When asked what they would want to know about a 
screening test, men reported
• “I would want to know if it works. If it works then great, as long 
as it is not going to have any side effects.” 
• “What is involved in getting the test itself, why do I need to get 
it, and when?” 
• When asked how effective a screening test would need to 
be for a man to consider having it done, patients reported:
• “I would just be acting with the assumption that it would be 
completely accurate.” 
Community (Patient) Perspective
• When asked about PSA screening specifically, men were less likely to want screening after 
hearing that the screening does not decrease the chances of dying from prostate cancer. 
• Men reported that they value the recommendation of their PCP regarding whether or not to 
have screening done 
• The outcomes of screening and available treatments were important to patients considering 
screening:
• “Give me some good reasons to get the screening and the treatment [and I will do it]. But … if 
you can’t do anything about it, then what’s the point ….” 
Intervention
• Create a handout about the risks and benefits of PSA screening intended to
• Decrease office time spent educating patients about PSA screening and allow more time 
to discuss other health concerns
• Equip patients with an understanding of PSA screening, risks and benefits, and the 
potential consequences of a positive test 
• Empower patients to make screening decisions based on their unique values
Response to Intervention
• Patients seemed interested in learning more about PSA screening because they 
hear “cancer” and immediately want to be tested. 
• Having the handout to give to patients helped facilitate the conversation and give 
people a chance to think over the potential consequences of a positive test before 
choosing to be screened. 
Evaluation of Effectiveness
• Survey patients about their confidence about their 
understanding of the following before and after receiving 
the handout and having a discussion with their physician
• What is PSA screening?
• What are the consequences of a positive test?
• What is involved in the treatment of prostate cancer?
• What are the risks and benefits of receiving treatment 
for prostate cancer? 
• Should I be screened for prostate cancer?
• **The effectiveness was not evaluated in this project due 
to the short duration of the research
Limitations 
• A handout can only do so much to 
facilitate a discussion between a patient 
and a provider. 
• Providers must remain diligent about 
educating their patients about PSA 
screening. 
• Patient perspectives were only collected 
from one clinic, so there is limited diversity 
in cultural backgrounds, relationship with 
PCP, and other important factors 
Future Interventions 
• Better screening tests for prostate cancer may 
be developed with the advances in medical 
imaging and genetic testing
• More specific recommendations should be 
developed to identify patients at higher risk for 
the more aggressive forms of prostate cancer
• A risk calculator could be developed to assist in 
the decision to screen patients for prostate 
cancer 
• Better treatments targeted to the genetic 
mutations present in a given patient’s cancer 
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